CD86 and precursor B-cell acute lymphoblastic leukemia: High circulating soluble CTLA-4 (sCTLA-4) levels have been detected in 70% of pediatric B-ALL patients with active disease (74), with elevated sCTLA-4 and CD86 levels associated with poor prognosis (70).